My watch list
my.bionity.com  
Login  

MannKind Corporation



MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas.

    First, we are continuing to execute the Technosphere® Insulin clinical trial program.
    Second, we are moving our second potential product – a therapeutic cancer vaccine
    – through Phase 1 clinical trials.
    Third, we have begun clinical testing of the next product candidate for use with our
    Technosphere® platform technology.

http://www.mannkindcorp.com

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MannKind_Corporation". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE